ArticleSkin health and disease2021

Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

J G S Veit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.